title: Tumoricidal alveolar macrophage and tumor infiltrating macrophage cell lines.
abstract: Continuous alveolar macrophage (AM) and tumor-infiltrated (TIM) cell lines have been generated from C57B16J mice by in vitro infection with the J2 retrovirus carrying the v-raf and v-myc oncogens. Four cloned AM cell lines (AMJ2-C8, AMJ2-C10, AMJ2-C11, AMJ2-C20) and 3 cloned TIM cell lines (TIMJ2-C4, TIMJ2-C7 and TIMJ2-C15) were expanded for further characterization. Flow cytometry detected the product of the raf gene in the cytoplasm of all these cell lines. Studies on the tumoricidal properties of these AM and TIM cell lines demonstrated differences in their response to a panel of known macrophage activators. Four of these cell lines (AMJ2-C8, AMJ2-C10, TIMJ2-C7 and TIMJ2-C15) were activated following exposure to recombinant murine interferon gamma (rMuIFN-gamma) but not lipopolysaccharide (LPS) or muramyl dipeptide (MDP). AMJ2-C20 was only activated by incubation with rMuIFN-gamma plus LPS. AMJ2-C11 and TIMJ2-C4 are the cell lines that most closely resembled the response pattern of the parental AM and TIM, since they could be activated by either the combination of rMuIFN-gamma plus LPS or rMuIFN-gamma plus MDP. Constitutive expression of MHC-class-II antigens was low on AMJ2-C11 or TIMJ2-C4 but was increased following exposure to rMuIFN-gamma. Neither cell line secreted substantial amounts of IL-1 or TNF but both secreted large amounts of IL-6. Thus these cell lines could be powerful tools to study AM and TIM activation and cytotoxicity.
authors.affiliation: Department of Oncology, Roche Research Center, Hoffmann-La Roche, Nutley, NJ 07110.
authors.forename: A V
authors.initials: AV
authors.lastname: Palleroni
authors.forename: L
authors.initials: L
authors.lastname: Varesio
authors.forename: R B
authors.initials: RB
authors.lastname: Wright
authors.forename: M J
authors.initials: MJ
authors.lastname: Brunda
mesh_terms: D000818:Animals; D002461:Cell Line, Transformed; D016207:Cytokines / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005240:Feasibility Studies; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D007155:Immunologic Factors / Q000494:pharmacology; D008262:Macrophage Activation; D008264:Macrophages / Q000737:chemistry / Q000166:cytology* / Q000276:immunology / Q000502:physiology; D051379:Mice; D027384:Oncogene Proteins v-raf; D011650:Pulmonary Alveoli / Q000166:cytology*; D015682:Retroviridae Proteins, Oncogenic / Q000032:analysis
chemical_list: D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D007155:Immunologic Factors; D015682:Retroviridae Proteins, Oncogenic; D027384:Oncogene Proteins v-raf